Alpha-1-antitrypsin is a so-called protease inhibitor, a type of enzyme inhibitor. It is produced in the liver but exerts its effects in the lungs, where it regulates immune cell activity. This ...

Alpha-1 Antitrypsin Deficiency And Related Disorders Publication Trend The graph below shows the total number of publications each year in Alpha-1 Antitrypsin Deficiency And Related Disorders.

Tiny fat bubbles carrying gene therapy have successfully repaired DNA in the lungs and liver of animals with alpha-1 antitrypsin deficiency — a promising leap toward treating humans with this ...

Alpha-1 Antitrypsin deficiency [AATD] is a type of disorder whereby the patient doesn't produce enough alpha-1 antitrypsin [AAT] protein, which is responsible for protecting the lungs and liver of ...

Two months after laying off 20% of its staff, Korro Bio says it has not retreated from its “3-2-1” corporate strategy as it prepares to release interim clinical data on its lead candidate KRRO-110 in ...

Qian, X., et al. (2025). Transferrin promotes fatty acid oxidation and liver tumor growth through PHD2-mediated PPARα hydroxylation in an iron-dependent manner. Proceedings of the National Academy of ...

Generation Alpha’s internet lingo is mutating faster than teachers, parents and AI models can keep up – potentially exposing youngsters to bullying and grooming that trusted adults and AI ...

Fitness influencer Brian "Liver King" Johnson was arrested Tuesday evening in Austin after making threats against Joe Rogan.

Researchers in Japan created an AI that can detect fatty liver disease from ordinary chest X-rays—an unexpected and low-cost method that could transform early diagnosis. The model proved highly ...

Troubled influencer Brian “Liver King” Johnson has been freed after his arrest for allegedly making terroristic threats against Joe Rogan — and immediately began posting bizarre videos again.

Thrivent Municipal Bond Fund underperformed the Bloomberg Municipal Bond Index by -.73% in the first quarter of 2025. For the trailing 12 months the Fund outperformed the Index by .18%.

Acute liver failure (ALF) in children differs from that observed in adults in both the etiologic spectrum and the clinical picture.